Breaking Barriers: The Benefits Of Being A Swiss Biotech
The lack of distractions from a large domestic market and a close proximity of research centers are just two advantages for the flourishing Swiss biotech sector, which enjoyed a bumper year in 2021, says its industry association.
You may also be interested in...
The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.
Recent executive changes in the industry include C-suite changes at AbbVie and Pharnext. Meanwhile, new directors were appointed at Zydus Lifesciences and FSD Pharma.
The German biotech plans to prevent chemotherapy-induced hearing loss and treat chronic hearing loss by targeting a potassium channel in the ear’s sensory hair cells as it tackles a widespread but side-lined area.